Living Cell Technologies Limited (LCT)

Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

Sign Up Today Ľ it's FREE! Already a member? Login now!

General Information
Company Name: Living Cell Technologies Limited
Stock Code: LCT
GICS Sub-Industry: Biotechnology
Market Cap ($M): 24
Equiv. Shares (M): 424

Current Price Data+
Current Price Open High Low Last Close Volume Price Movement
 $ 0.055 $ 0.055 $ 0.055 $ 0.055 $ 0.057 1,000 $ -0.002  -3.509 %

Company Overview

Business Description:
Living Cell Technologies (LCT) develops cell therapies to treat diseases with high unmet clinical needs. The Australasian biotechnology company is a global pioneer in the field of cell encapsulation and implantation for human therapeutics. To date, the company has taken two therapeutic candidates into clinical development: DIABECELL¬ģ for the treatment of type 1 diabetes and NTCELL¬ģ, which is in Phase I clinical trials in New Zealand for the treatment of Parkinson‚Äôs disease.

Financial Summary
Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2014  A -6.8 -1.9 -- 0.0 0.0 0.0 --
2013  A -3.0 -0.8 -- 0.0 0.0 0.0 --
2012  A 5.7 1.7 -- 3.7 0.0 0.0 --
Source: Aspect actuals / Thomson IBES estimates

Peer Comparison
EPS Growth (%) P/E (%) Dividend Yield (%)
Company Mkt Cap 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F
Bionomics (BNO) $203 M -- -- -- 62.9870 -- 4.9189 0.00 0.00 0.00
CSL (CSL) $43,712 M 0.0899 0.3357 0.0809 32.2890 24.1744 22.3650 1.30 1.73 1.97
Living Cell (LCT) $25 M -- -- -- -- -- -- 0.00 -- --
Mesoblast (MSB) $1,342 M -- -- -- -- -- -- 0.00 0.00 0.00
Sirtex Medical (SRX) $2,010 M 0.2906 0.5729 0.5049 86.0775 54.7260 36.3646 0.39 0.54 0.91

Market Comparison
Earnings P/E Ratio P/B Ratio P/E Growth P/S Ratio
LCT -- -- 2.42 -- 2.75
Market 0.98 13.9 1.02 1.14 2.82
Sector 0.78 17.1 2.65 1.17 7.70

Name Position Start Date
Professor Robert Bartlett Elliott Executive Director 15 January 2004
Mr Robert Moyse Willcocks Non-Executive Director 29 March 2011
Mr Laurrie Hunter Non-Executive Director 25 August 2006
Dr Bernard Tuch Non-Executive Director 19 July 2011
Mr Roy James Austin Non-Executive Director,Non-Executive Chairman 25 February 2011

Name Position
Ken Taylor Acting CEO
Kenneth (Ken) P Taylor Chief Executive Officer
Nicholas (Nick) John Victor Geddes Company Secretary
Robert Elliott Director, Clinical Research & Innovation
John Cowan Head of Finance & Administration

Substantial Shareholders
Holding Name
25,000,000 (7.00%) Otsuka Pharmaceutical Factory, Inc
24,150,408 (6.76%) Palmert Members Limited
24,150,408 (6.76%) Coalco International Limited
17,792,675 (4.98%) Persistency Private Equity Limited (formerly Prospector Limited)

Calendar of Events
Date Event
17 February 2016 Report (Interim)
16 October 2015 Report (Annual)
14 August 2015 Report (Prelim)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at


Trade Shares Online from $19.95^
Free Guides

The SMH Guide to Estate Planning

Everyone wants their financial affairs to be in the best possible state when they die so that their loved ones can enjoy the benefits of their legacy without dispute or conflict.

More details...


Markets melt up

By Michael McCarthy (chief market strategist, CMC Markets) 19/12/2014 | Traders and investors caught short heading into the FOMC scrambled for cover in Europe and the US, in many cases driving indices to their best one day performance for 2015.

Aussie Investors take their foot off the accelerator

By Betty Lam (Sales Trader, CMC Markets) 18/12/2014 | Lead by the Fed-fervour offshore, Australians shares jumped on the Yellen cheer wagon. The material and energy stocks were back in vogue as both sectors gained over 3% in morning trade.

Fed Feeds Frenzy

By Michael McCarthy (chief market strategist, CMC Markets) 18/12/2014 | In spite of a frenzied pre-mortem, a benign statement from the US Federal Reserve‚Äôs Open Market Committee and steadying commodity markets drove investors back into share markets overnight. A calmer, stronger ruble helped offset European growth fears, highlighted in the overnight session by further declines in inflation.

Household brands Woolworths and Telstra Heavy Lifting

By Betty Lam (Sales Trader, CMC Markets) 11/12/2014 | Offshore jitters sent ripples through to Australian stocks. The open saw the local equities take 65 points off the index, catalysed by a mass-exit in energy stocks, yet again.

Steady open as Woodside investors wait on details of possible Wheatstone acquisition

By Ric Spooner (Chief Market Analyst, CMC Markets) 10/12/2014 | Yesterday‚Äôs news on Greek politics and China‚Äôs bond market came at a time when US and European stock markets have extended rallies and pushed valuations higher. This makes those markets vulnerable to downward corrections as profit takers act to avoid missing out.

MYEFO and Lima - December could be nasty.

BR Securities Australia Pty Ltd 2/12/2014 | December 2014 could go down as a nasty moment in Australian finance. MYEFO will reveal a deteriorating budget deficit and the UNFCCC meeting in Lima, Peru will provide the agreement, to be ratified in Paris in 2015, on how much (or little) CO2 is to be allowed into the atmosphere from 2020.


Sponsored Links